You cannot fully ensure patient safety in unregulated markets—but you can refuse to enter them. Unregulated medicines, dietary supplements, and compounded products sold online and through informal channels operate outside the quality controls, testing requirements, and traceability systems that protect patients who buy from licensed pharmacies. The stakes are highest for people managing chronic illnesses, older adults, and caregivers searching for relief from expensive or hard-to-find treatments. A March 2026 report from the Patients Association found that patients knowingly purchase unregulated medicines online despite full awareness of the dangers: counterfeits that don’t work, products laced with harmful substances, and contaminated formulations. They do it because they see no alternative—because legal supplies have dried up, prices are unaffordable, or promises of faster relief feel like the only option left.
The scale of this problem has expanded rapidly. The World Health Organization estimates that more than half of all medicines purchased from online pharmacies—many of them illegal international fronts masquerading as legitimate retailers—are counterfeit. Globally, more than 1 in 10 medicines in low- and middle-income countries are substandard or falsified. No country remains untouched. When patients buy from unregulated sources, they are gambling with their health. The products may contain wrong doses, toxic contaminants, prescription drugs hidden inside supplements marketed as natural, or nothing of the claimed ingredient at all.
Table of Contents
- Why Shortages and Affordability Force Patients Into Illegal Markets
- The Counterfeit Crisis—How Fake Medicines Reach Patients
- FDA Enforcement Actions in 2026—What Triggered the Warnings
- Dietary Supplements—Natural Does Not Mean Safe or Regulated
- Contaminated Supplements and the Specific Dangers to Older Adults
- The Global Response—WHO and International Enforcement
- Affordability and Access—The Root Cause Driving Illicit Markets
Why Shortages and Affordability Force Patients Into Illegal Markets
Drug shortages at legitimate pharmacies have become a chronic driver of illicit pharmacy use. When legal suppliers cannot meet patient demand due to regulatory constraints and limited approved sources, patients seeking essential medications turn to illegal channels. Once they’ve purchased from an unregulated source, research shows they often continue buying additional medications from those same illicit sellers, compounding both economic and public health risk. A patient who initially sought one unavailable medication from an illegal online pharmacy may end up sourcing multiple prescriptions from the same untrustworthy vendor, creating repeated exposure to counterfeits and contaminated products.
Affordability is the other major force. Patients often cannot afford medications at lawful pharmacies, especially when managing multiple chronic conditions. A dementia caregiver searching for treatments to manage behavioral symptoms, or an older adult purchasing medications for Parkinson’s disease, arthritis, and diabetes simultaneously, faces cumulative costs that exceed their budget. The illegal market exploits this desperation by offering significantly lower prices—prices that seem impossible until the patient realizes the product doesn’t work, causes unexpected side effects, or never contained the active ingredient at all.
The Counterfeit Crisis—How Fake Medicines Reach Patients
In April 2026, a Michigan State University report found that 1 in 5 consumers had been deceived into purchasing counterfeit medications. Criminal enforcement campaigns that same year led to 269 arrests and the dismantling of 66 criminal groups worldwide involved in illegal online medicine sales. Yet for every criminal network disrupted, new ones emerge. Certain medications have become prime targets for counterfeiters: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are now among the most attractive counterfeits because of high demand, high prices, and the difficulty many patients face obtaining them through legal channels. Counterfeit and unapproved drugs pose risks far beyond incorrect dosing.
Microbiological contamination—bacterial, fungal, or viral contamination introduced during illegal manufacturing—can cause life-threatening infections. A counterfeit injectable medication might contain bacteria that triggers a severe bloodstream infection. A compounded supplement might grow mold during storage in an uncontrolled facility. These risks are not theoretical: the FDA continues to receive adverse event complaints and reports of patient deaths linked to unapproved stem cell products, compounded medications, and counterfeit drugs purchased online. The contamination is often invisible to the patient; symptoms may not appear until serious damage has occurred.
FDA Enforcement Actions in 2026—What Triggered the Warnings
Between May 21 and June 15, 2026, the FDA received more than 1,700 adverse event reports associated with compounded semaglutide and tirzepatide—the active ingredients in GLP-1 drugs. The agency issued 25 warning letters in mid-June 2026 to telehealth companies making false or misleading promotional claims about these products. Compounded GLP-1 medications are not FDA-approved; they are made by pharmacies under looser regulations meant for patients who cannot use the approved versions. Yet a consumer survey revealed that only 17% of consumers know compounded GLP-1 products are not FDA-approved, despite 84% saying they would want FDA approval.
The knowledge gap leaves patients vulnerable to misleading marketing that implies these products are equivalent to prescription versions like Ozempic. The FDA also intensified warnings against unapproved stem cell products marketed online as treatments for neurological conditions, joint pain, and degenerative diseases. The Center for Biologics Evaluation and Research issued warning letters targeting companies marketing allogeneic stem cell products derived from umbilical cord blood or Wharton’s Jelly—products without evidence of safety or efficacy. For families of dementia patients desperately seeking slowing or reversing cognitive decline, these unproven stem cell clinics represent false hope packaged as innovation. The FDA has documented patient harm and deaths linked to these unapproved products.
Dietary Supplements—Natural Does Not Mean Safe or Regulated
Dietary supplements represent a category of products that exist in a regulatory gray zone. The FDA does not require pre-market approval for supplements the way it does for drugs. This means supplements reach consumers with minimal safety testing. According to data analyzed from 2004 to 2013, dietary supplements caused over 23,000 emergency department visits annually in the United States, with an average of 2,154 hospitalizations per year. Those numbers are striking: more than 63 ED visits per day, every day, linked to adverse reactions from unregulated or poorly regulated supplements.
Weight loss and energy supplements account for approximately 3,399 of those annual ED visits—30% of visits by women and 17.6% by men. Young adults aged 20 to 34 represent 28% of supplement-related ED visits, but unsupervised children represent 21.2%. The most dangerous supplements often contain hidden prescription drugs: a product marketed as natural arthritis relief, such as Artri King, might contain dexamethasone (a corticosteroid), diclofenac (a nonsteroidal anti-inflammatory), or methocarbamol (a muscle relaxant). Patients believe they are taking a botanical remedy and instead ingest undisclosed pharmaceutical drugs at unknown doses. An older adult with dementia, already on multiple medications, could experience dangerous drug interactions without knowing what they actually consumed.
Contaminated Supplements and the Specific Dangers to Older Adults
The FDA issued warnings in 2026 about Tejocote Root Supplements—products that had been substituted with toxic yellow oleander, a plant with cardiac glycosides that can cause severe heart problems. Other supplement products tested positive for elevated lead levels. These are not rare anomalies; they reflect the widespread quality control failures in unregulated and loosely regulated supplement manufacturing.
Older adults and people with dementia are at particular risk because they often take more medications and supplements than younger adults, increasing the likelihood of adverse interactions or cumulative toxicity. Swallowing problems, a common issue in advancing dementia, make older patients even more vulnerable to harm from counterfeit or contaminated pills and capsules. Microbiological contamination in a supplement could trigger a respiratory or GI infection in someone with swallowing difficulties. The absence of quality control means a patient might receive tablets of inconsistent size, hardness, or composition batch to batch—a manufacturing variance that could worsen choking risk or cause unexpected toxicity if a batch is contaminated or over-dosed.
The Global Response—WHO and International Enforcement
On May 22, 2026, the Fight the Fakes Alliance—a coalition including the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)—delivered a statement at the World Health Assembly (WHA79) focused on substandard and falsified medicines. The statement emphasized the need to involve technical experts and people with lived experience of harm in the fight against unregulated products. On May 7, 2026, the WHO issued Medical Product Alert N°1/2026 regarding substandard contrast agents, identifying Iohexol and Iodixanol products that failed quality standards.
These alerts are tools of transparency—ways to warn healthcare systems and patients about products already circulating. Yet alerts arrive after harm has occurred. A patient may have already purchased a counterfeit medication or contaminated supplement before the WHO or FDA issues a warning. The lag between discovery and public notification creates a window of vulnerability that unregulated suppliers exploit.
Affordability and Access—The Root Cause Driving Illicit Markets
The fundamental driver behind the rise of unregulated medicines is lack of access to affordable treatments through legal channels. Patients do not prefer to buy counterfeits or unregulated products; they do so because approved medicines are too expensive or unavailable. A dementia caregiver managing a family member’s disease progression while juggling their own health care costs faces impossible choices: pay for a prescribed medication or pay rent. The illicit market exploits this reality.
Illegal online pharmacies advertise at a fraction of the price of legitimate retailers, and patients, facing genuine hardship, take the risk. Until patients have genuine access to affordable, quality medicines through legal channels, unregulated markets will continue to thrive. Regulatory enforcement and criminal prosecution of illegal sellers addresses the supply side, but without addressing the affordability and access crisis on the demand side, patients will continue to be pushed into dangerous alternatives. For caregivers and patients managing chronic neurological diseases, this means advocating for price transparency, insurance coverage, and pharmaceutical assistance programs as actively as avoiding unregulated sellers.
- —
